United Bioscience (UBC) Scientific Policy Director Appointed to Medicare Coverage Advisory Committee (MCAC)
Health Care Industry Executive and Consultant Dr. Bryan R. Luce Will Help Guide Medicare Policy Over the Next Two Years
BETHESDA, MD (May 27, 2005) - United BioSource Corporation (UBC), a leading provider of comprehensive evidence-based drug evaluation services, today announced that Dr. Bryan R. Luce has been invited to serve as a member of the Medicare Coverage Advisory Committee (MCAC). Dr. Luce is the Scientific Policy Director and founder of The MEDTAP Institute, the scientific research arm of UBC.
"I am honored to contribute to this important group and help guide our nation's Medicare policy," said Dr. Luce. "As the emphasis on evidence-based medicine continues to grow, especially in light of the Medicare Modernization Act, the government is under greater pressure to make informed and supportable coverage decisions. UBC and The MEDTAP Institute have become industry leaders in exactly this sort of evaluation, so our expertise should be very useful to the Committee."
Dr. Bryan Luce has spent many years as a health care industry executive, and has served as a consultant to numerous government agencies as well as pharmaceutical and device firms worldwide. From 1995 to 2002, Dr. Luce was Chairman, President and CEO of MEDTAP. Previously, he held positions as the Director of Battelle's Centers for Public Health Research and Evaluation, Director of the Office of Research and Demonstrations at the Health Care Financing Administration, and Senior Analyst in the former Congressional Office of Technology Assessment.
Luce will serve on the MCAC for a period of two years beginning in the summer of 2005. The MCAC advises the Centers for Medicare and Medicaid Services (CMS) on whether specific medical items and services are reasonable and necessary under Medicare law. It performs this task through a careful review and discussion of specific clinical and scientific issues, and it does so in an open and public forum. MCAC members are valued for their background, education and expertise in a wide variety of scientific, clinical and other related fields.
About UBC
United BioSource Corporation (UBC) delivers evidence-based solutions to optimize the medical and commercial potential of pharmaceuticals, biotechnology, medical devices, and diagnostics. UBC is based in Bethesda, Maryland. For more information about UBC, visit www.unitedbiosource.com or call 240-644-0420.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
